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Abstract
OBJECTIVE—To determine whether an individualized growth standard (IS) improves
identification of preterm small-for-gestational-age (SGA) neonates at risk of developing moderate/
severe cerebral palsy (CP) or death.
STUDY DESIGN—Secondary analysis of data from a randomized trial of MgSO4 for prevention
of CP or death among anticipated preterm births. Singleton non-anomalous liveborns delivered
before 34 weeks’ were classified as SGA (< 10th % for their GA) by a population standard (PS) or
an IS (incorporating maternal age, height, weight, parity, race/ethnicity, and neonatal gender). The
primary outcome was prediction of moderate or severe CP or death by age 2.
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RESULTS—Of 1588 eligible newborns, 143 (9.4%) experienced CP (N=33) or death (N=110).
Forty-four (2.8%) were SGA by the PS and 364 (22.9%) by the IS. All PS-SGA newborns also
were identified as IS-SGA. SGA newborns by either standard had a similarly increased risk of CP
or death (PS: RR 2.4, 95% CI 1.3–4.3 vs. IS: RR 1.8, 95% CI 1.3–2.5, respectively). The
similarity of RRs remained after stratification by MgSO4 treatment group. The IS was more
sensitive (36% vs. 6%, p <.001), but less specific (78% vs. 98%, p <.001) for CP or death. ROC
curve analysis revealed a statistically lower AUC for the PS, although the ability of either method
to predict which neonates would subsequently develop CP or death was poor (PS: 0.55, 95% CI
0.49–0.60 vs. IS: 0.59, 95% CI 0.54–0.64, p<.001).
CONCLUSION—An individualized SGA growth standard does not improve the association with,
or prediction of, CP or death by age 2.
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Fetal growth restriction traditionally has been defined according to liveborn growth curves
based on a population standard.1 Some investigators have noted, however, that such a
definition is suboptimal because it includes birth weights that result from both normal
physiologic variation and pathologic states.2 Consequently, the ability to identify those
fetuses or newborns with truly abnormal growth, who are most at-risk for both short-term
and long-term adverse outcomes, is compromised by the use of such a standard.
As a result, a definition of growth restriction based on an individualized standard has been
proposed.3 An individualized standard is based on the predicted growth potential of a given
individual and therefore should improve the accuracy with which truly at-risk fetuses or
newborns are identified. Indeed, several studies have suggested that certain perinatal
morbidities are better identified using an individualized standard as opposed to a population
standard. Gardosi and Francis, for example, found that threatened preterm labor, antepartum
hemorrhage, pregnancy-induced hypertension, preeclampsia, stillbirth, and early neonatal
death all were better identified using the individualized standard.4
The potential benefit of using individualized birthweight standards to help predict long-term
neurodevelopmental adverse outcomes, however, is not known. While it is well established
that adverse neurodevelopmental outcomes such as cerebral palsy (CP) are associated with
fetal growth restriction,5 many of those who are diagnosed with adverse
neurodevelopmental outcomes based on population standards do not have evident growth
abnormalities. If individualized standards could improve identification of those newborn
who are pathologically growth restricted, and thereby the identification of those at risk for
long-term disability, counseling and the targeting of early intervention could both be
improved. Accordingly, the primary aim of this study was to determine whether an
individualized growth standard, compared to a population-based standard, would improve
identification of SGA neonates destined to develop moderate or severe CP or death by 2
years of age.
Materials and Methods
This is a secondary analysis of data from a randomized trial (i.e., the BEAM study) of
magnesium sulfate for prevention of moderate/severe CP or death among infants born
prematurely. Full details of this study have been described previously.6 In brief, women
judged to be at high risk for preterm birth prior to 32 weeks of gestation were randomized to
either a magnesium sulfate or placebo infusion. After delivery, liveborn infants were
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followed for 2 years with detailed developmental assessments performed by trained
examiners.
The present analysis includes all non-anomalous singleton liveborns in the BEAM study
who delivered prior to 34 weeks of gestation. Each newborn’s birth weight was used to
determine whether it was small-for-gestational-age (SGA), defined as less than the 10th
percentile, according to a population standard or an individualized standard. The population
standard used was that proposed by Alexander et al, which is stratified according to neonatal
gender and ethnicity.7 Since the continuous values of the population standard were not
available, the following approach was used to approximate these values: an Arc-Tan based
transformation of birth weights (ArcTan((weight/1000)2)*2/π) was performed, and the
corresponding continuous values of the population standard were calculated by a simple
approximation method based on the linear connection of the 3rd, 10th, 50th and 90th
percentiles, provided by Alexander et al., in the different race, infant gender, and gestational
age groups.8 The individualized standard used was that proposed by Gardosi et al, which
takes into account maternal age, height, weight, parity, race/ethnicity, and neonatal gender.3
The software GROW (Gestation Related Optimal Weight) at www.gestation.net was used to
calculate the individualized standard.
The association of the primary outcome, moderate/severe CP or death by 2 years of age,
with the diagnosis of SGA by each type of standard was presented as the relative risk with
95% confidence intervals. The ability of each type of standard to accurately classify
newborns, based on their SGA status, according to whether they developed CP or death was
assessed using sensitivity, specificity, and the area under the receiver operating
characteristic curve (AUC-ROC).
Cerebral palsy was diagnosed by an annually-certified pediatrician or pediatric neurologist if
two or more of the following three features were present: a delay of 30% or more in gross
motor developmental milestones (e.g., inability to sit without arm support by 9.5 months or
walk by 17 months of corrected age); abnormality in muscle tone (e.g., scissoring), 4+ or
absent deep-tendon reflexes, or movement abnormality (e.g., posturing or gait asymmetry);
or persistence of primitive reflexes or absence of protective reflexes. When CP was
diagnosed, the Gross Motor Function Classification System (GMFCS) was used to assess
severity.
In addition, the associations of the SGA diagnosis with secondary outcomes, including
respiratory distress syndrome, necrotizing enterocolitis, grade 3 or 4 intraventricular
hemorrhage, retinopathy of prematurity, seizures, or sepsis, were determined.
All analyses were performed with R (http://www.r-project.org/) and SAS (SAS Institute Inc,
Cary, NC). P < .05 was used to define statistical significance, and all tests were two tailed.
No adjustments were made for multiple comparisons. McNemar's test for classification
agreement was used for the comparison of sensitivity or specificity.9 A nonparametric
statistical method was used for the comparison of the AUC-ROCs.10 All analyses were
repeated by treatment subgroups (placebo vs. magnesium sulfate). Institutional review board
approval was obtained prior to the initiation of the study.
Results
One thousand five hundred and eighty-eight newborns met inclusion criteria. Characteristics
of the study population are presented in Table 1. Of these, 364 (22.9%) were identified as
SGA according to the individualized standard (IS) and 44 (2.8%) were identified as SGA
according to the population standard (PS). Forty-four newborns met SGA criteria by both
standards (i.e., all PS-SGA newborns also were identified as IS-SGA).
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One hundred and forty-three neonates (9.4%) developed either moderate or severe CP (n =
33, 2.2 %) or death (n = 110, 7.2%) by 2 years of age. Moderate or severe CP was seen in
14.4% of the infants defined as SGA by the IS and in 21.4% of the infants defined as SGA
by the PS. Neonates defined as SGA by either the population standard or by the individual
standard were significantly more likely to develop moderate/severe CP or death, although
the magnitudes of the associations were similar for both types of standards (Table 2).
The test characteristics of the different growth standards for prediction of the primary
outcome also are presented in Table 2. While the individualized standard had a significantly
greater sensitivity for the primary outcome, its specificity was significantly lower. Although
the AUC for prediction of the primary outcome was greater for the individualized standard,
this difference was small and unlikely to have clinical relevance. Moreover, the AUC for
either the individualized or population standard demonstrates that either standard is poorly
predictive of CP or death.
The results were similar for prediction of the various secondary outcomes. While the
individualized standard appeared to be better at predicting these outcomes, the difference
was small in magnitude. In addition, the ability of either growth standard to predict any
secondary outcome was repeatedly poor (Table 3). The AUC values indicate that prediction
of these outcomes was at best barely better than chance.
Results did not vary by treatment group (data not shown).
Comment
In this study, we evaluated whether the use of an individualized growth standard would
enhance the ability to identify preterm neonates who were most likely to develop moderate
or severe CP or die. In addition, we evaluated whether an individualized growth standards
could better predict other significant morbidities associated with preterm birth. Our results
do not support the concept that the predictive ability of an individualized standard is
clinically superior to that of a population standard.
These results stand in contrast to those of some investigators whose studies have suggested
that use of an individualized standard could improve identification of pathologically grown
neonates. For example, Gardosi and Francis demonstrated that the presence of a SGA
neonate, as classified by an individualized standard as opposed to a population-based
standard, was significantly more likely to be associated with pregnancies that had been
complicated by threatened preterm labor, antepartum hemorrhage, pregnancy-induced
hypertension, preeclampsia, stillbirth, and early neonatal death.4 Others have reported that
adverse outcomes subsequent to birth, such as Apgars < 4 at 5 minutes, long hospital stays,
or neonatal death, were more strongly associated with SGA births classified according to the
individualized standard.11–13
In contrast, other investigators, when examining antepartum or short-term neonatal
outcomes, have not found that an individualized standard is superior. Hutcheon et al,
studying over 780,000 births from a Swedish birth registry, found that an individualized
birth weight standard had a similar ability to predict perinatal death as a population-based
standard that did not adjust for maternal characteristics.14 Larkin et al studied over 32,000
births from an American population and similarly found no significant difference in the
ability of population-based or individualized standards to predict which women were more
likely to have pregnancies complicated by perinatal morbidity.15 Our work supports and
extends the concept that outcomes are similar regardless of which type of growth standard is
used. By focusing upon a preterm population only, we were able to assess immediate
complications related to prematurity, as well as longer term complications, such CP or infant
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mortality. Regardless of which outcome was examined, associations and predictive abilities
were similar between the two types of growth standards.
The population for this study was derived from a randomized trial that assessed whether
magnesium sulfate was efficacious for prevention of moderate or severe CP, and was
predominantly composed of neonates born after premature preterm rupture of the
membranes. As such, further investigation will need to determine whether these findings are
generalizable to all women, such as those with pregnancy complications characterized by
chronic placental insufficiency (e.g., preeclampsia, chronic abruption), who deliver preterm.
The accurate prediction of which prematurely born neonates will die or develop CP would
be of great value, as it would allow not only better counseling but offer the potential that
early interventions in the neonatal period could reduce the frequency of these adverse
events. Although neonates who are SGA according to population-based growth are at higher
risk of death or CP, the predictive ability of the SGA designation for these outcomes has
been poor. Unfortunately, designation of SGA status through the use of individualized
standards does not appear to improve this predictive ability. In light of the additional work
that is necessary to establish an individualized standard, these findings do not support their
introduction into clinical practice at present, and suggest that further work will need to be
done to establish whether their use is supported by enhancements in clinical outcomes.
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Table 1
Characteristics of the study population
Characteristic N = 1588
Weeks of gestation at randomization 28.2 ± 2.4
Maternal age (years) 26.3 ± 6.3
Maternal height (cm) 162.9 ± 7.5
Maternal pre-pregnancy weight (kg) 69.5 ± 18.9
Maternal pre-pregnancy BMI (kg/m2) 26.2 ± 6.8
Maternal race/ethnicity
  Black 719 (45.3%) 1.
  White 598 (37.7%) 2.
  Hispanic 235 (14.8%) 3.
  Other 36 (2.3%) 4.
Married* 760 (48.0%) 5.
Nulliparous 567 (35.7%) 6.
Previous preterm delivery 450 (28.3%) 7.
Cigarette use during pregnancy 475 (29.9%)
Data presented as mean ± standard deviation or n (%)
*
Marital status unknown for 4 women
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Table 2






Relative risk (95% CI)** 1.8 (1.3 – 2.5) 2.4 (1.3 – 4.3) --------
Sensitivity 36% 6% <.001
Specificity 78% 98% <.001
Area under the curve 0.59 (0.54–0.64) 0.55 (0.49–0.60) <.001
*
P-value based on McNemar's test for classification agreement (sensitivity/specificity) or non-parametric comparison of areas under the ROC
curves.
**
Referent = non-small-for-gestational-age neonates
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Table 3






RDS 0.52 (0.49 – 0.55) 0.43 (0.40 – 0.46) <.001
Necrotizing enterocolitis 0.54 (0.49 – 0.58) 0.49 (0.45 – 0.54) <.001
IVH, grade 3 or 4 0.44 (0.34 – 0.54) 0.38 (0.26 – 0.49) 0.04
ROP 0.56 (0.53 – 0.60) 0.48 (0.45 – 0.52) <.001
Seizures 0.55 (0.46 – 0.64) 0.51 (0.40 – 0.61) 0.15
Sepsis 0.57 (0.54 – 0.61) 0.52 (0.49 – 0.56) <.001
RDS = respiratory distress syndrome; IVH = intraventricular hemorrhage; ROP = retinopathy of prematurity
*
P-value based on non-parametric comparisons for area under the ROC curves.
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